About Clementia
Clementia is a company based in Dorval (Canada) founded in 2012 was acquired by Ipsen in February 2019.. Clementia has raised $92.5 million across 5 funding rounds from investors including UCB, Ipsen and Orbimed. Clementia offers products and services including Oncology Medicines, Rare Disease Treatments, and Neuroscience Products. Clementia operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Dorval, Canada
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ipsen Pharma
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Clementia
Clementia offers a comprehensive portfolio of products and services, including Oncology Medicines, Rare Disease Treatments, and Neuroscience Products. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatments for cancers and tumors in oncology field
Therapies for rare genetic and liver disorders
Medications for debilitating neurological conditions
Unlock access to complete
Unlock access to complete
Leadership Team
165 people
Software Development Team
160 people
Product Management Team
44 people
Human Resources and Administration
41 people
Finance and Accounting
36 people
Senior Team
32 people
Sales and Marketing
30 people
Operations Team
29 people
Unlock access to complete
Funding Insights of Clementia
Clementia has successfully raised a total of $92.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $60 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $60.0M
- First Round First Round
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2015 | Amount | Series B - Clementia | Valuation |
investors |
|
| Jun, 2015 | Amount | Debt – Conventional - Clementia | Valuation |
investors |
|
| Jan, 2015 | Amount | Series A - Clementia | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Clementia
Clementia has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include UCB, Ipsen and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Clementia
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Clementia
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Clementia Comparisons
Competitors of Clementia
Clementia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for rare and orphan diseases
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics to treat rare genetic diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Clementia
Frequently Asked Questions about Clementia
When was Clementia founded?
Clementia was founded in 2012.
Where is Clementia located?
Clementia is headquartered in Dorval, Canada. It is registered at Dorval, Quebec, Canada.
Who is the current CEO of Clementia?
David Loew is the current CEO of Clementia.
Is Clementia a funded company?
Clementia is a funded company, having raised a total of $92.5M across 5 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Jun 01, 2012.
What does Clementia do?
Clementia was founded in 2012 in Dorval, Canada, within the biotechnology sector focused on rare diseases. Treatments for conditions like Fibrodysplasia Ossificans Progressiva are advanced through retinoic acid receptor gamma science. The lead candidate, Palovarotene, is investigated as an agonist to inhibit abnormal bone growth. Orphan Drug Designation was granted by the FDA in 2014, and Orphan Medicinal Product Designation was received from the EMA.
Who are the top competitors of Clementia?
Clementia's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Clementia offer?
Clementia offers Oncology Medicines, Rare Disease Treatments, and Neuroscience Products.
Who are Clementia's investors?
Clementia has 9 investors. Key investors include UCB, Ipsen, Orbimed, Janus Henderson Investors, and RA Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.